# An Open-label DDI Study of Omaveloxolone in Healthy Subjects

> **NCT05909644** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 20 (actual)

## Conditions studied

- Healthy Adult Subjects

## Interventions

- **DRUG:** Omaveloxolone
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT05909644
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-05
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05909644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05909644, "An Open-label DDI Study of Omaveloxolone in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05909644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*